Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Two Sigma Investments LP grew its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 41.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 891,279 shares of the company’s stock after acquiring an additional 260,318 shares during the quarter. Two Sigma Investments LP owned about 0.39% of Gossamer Bio worth $806,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Octagon Capital Advisors LP lifted its position in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after acquiring an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after acquiring an additional 526,495 shares in the last quarter. Monaco Asset Management SAM lifted its position in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after acquiring an additional 1,520,721 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Gossamer Bio by 14.6% in the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock valued at $3,244,000 after acquiring an additional 457,179 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Trading Up 5.6%

Shares of NASDAQ GOSS opened at $1.33 on Friday. The company has a market cap of $302.31 million, a price-to-earnings ratio of -4.16 and a beta of 1.85. Gossamer Bio, Inc. has a 12-month low of $0.50 and a 12-month high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.03.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. Equities research analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Analyst Upgrades and Downgrades

GOSS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, The Goldman Sachs Group increased their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, May 16th.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.